These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27868366)

  • 1. Effects of gemigliptin, a dipeptidyl peptidase-4 inhibitor, on lipid metabolism and endotoxemia after a high-fat meal in patients with type 2 diabetes.
    Ahn CH; Kim EK; Min SH; Oh TJ; Cho YM
    Diabetes Obes Metab; 2017 Mar; 19(3):457-462. PubMed ID: 27868366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study).
    Ahn CH; Han KA; Yu JM; Nam JY; Ahn KJ; Oh TK; Lee HW; Lee DH; Kim J; Chung CH; Park TS; Kim BJ; Park SW; Park HK; Lee KJ; Kim SW; Park JH; Ko KP; Kim CH; Lee H; Jang HC; Park KS
    Diabetes Obes Metab; 2017 May; 19(5):635-643. PubMed ID: 28026912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
    Rhee EJ; Lee WY; Min KW; Shivane VK; Sosale AR; Jang HC; Chung CH; Nam-Goong IS; Kim JA; Kim SW;
    Diabetes Obes Metab; 2013 Jun; 15(6):523-30. PubMed ID: 23320436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.
    Kim SH; Jung E; Yoon MK; Kwon OH; Hwang DM; Kim DW; Kim J; Lee SM; Yim HJ
    Eur J Pharmacol; 2016 Oct; 788():54-64. PubMed ID: 27298192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.
    Han SY; Yoon SA; Han BG; Kim SG; Jo YI; Jeong KH; Oh KH; Park HC; Park SH; Kang SW; Na KR; Kang SW; Kim NH; Jang Y; Kim B; Shin S; Cha DR
    Diabetes Obes Metab; 2018 Feb; 20(2):292-300. PubMed ID: 28719008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study).
    Lim S; Han KA; Yu J; Chamnan P; Kim ES; Yoon KH; Kwon S; Moon MK; Lee KW; Kim DJ; Kim M; Wongtanate M; Kim EY; Kim SH; Lee MK;
    Diabetes Obes Metab; 2017 Jan; 19(1):87-97. PubMed ID: 27619558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes.
    Yang SJ; Min KW; Gupta SK; Park JY; Shivane VK; Pitale SU; Agarwal PK; Sosale A; Gandhi P; Dharmalingam M; Mohan V; Mahesh U; Kim DM; Kim YS; Kim JA; Kim PK; Baik SH
    Diabetes Obes Metab; 2013 May; 15(5):410-6. PubMed ID: 23170990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A dipeptidyl peptidase-IV inhibitor improves hepatic steatosis and insulin resistance by AMPK-dependent and JNK-dependent inhibition of LECT2 expression.
    Hwang HJ; Jung TW; Kim BH; Hong HC; Seo JA; Kim SG; Kim NH; Choi KM; Choi DS; Baik SH; Yoo HJ
    Biochem Pharmacol; 2015 Nov; 98(1):157-66. PubMed ID: 26297911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.
    Matikainen N; Mänttäri S; Schweizer A; Ulvestad A; Mills D; Dunning BE; Foley JE; Taskinen MR
    Diabetologia; 2006 Sep; 49(9):2049-57. PubMed ID: 16816950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial.
    Hermansen K; Bækdal TA; Düring M; Pietraszek A; Mortensen LS; Jørgensen H; Flint A
    Diabetes Obes Metab; 2013 Nov; 15(11):1040-8. PubMed ID: 23683069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of fixed-dose combination therapy with gemigliptin (50 mg) and rosuvastatin compared with monotherapy in patients with type 2 diabetes and dyslipidaemia (BALANCE): A multicentre, randomized, double-blind, controlled, phase 3 trial.
    Bae JC; Min KW; Kim YH; Kim KA; Hong EG; Park CY; Han S; Cha BS
    Diabetes Obes Metab; 2019 Jan; 21(1):103-111. PubMed ID: 30084112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Glycemic Control on Chylomicron Metabolism and Correlation between Postprandial Metabolism of Plasma Glucose and Chylomicron in Patients with Type 2 Diabetes Treated with Basal-bolus Insulin Therapy with or without Vildagliptin.
    Okajima F; Emoto N; Kato K; Sugihara H
    J Atheroscler Thromb; 2017 Feb; 24(2):157-168. PubMed ID: 27397060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dipeptidyl peptidase-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels in patients with type 2 diabetes: A randomized controlled trial.
    Onoue T; Goto M; Wada E; Furukawa M; Okuji T; Okada N; Kobayashi T; Iwama S; Sugiyama M; Tsunekawa T; Takagi H; Hagiwara D; Ito Y; Morishita Y; Seino Y; Suga H; Banno R; Hamada Y; Ando M; Yamamori E; Arima H
    PLoS One; 2020; 15(1):e0228004. PubMed ID: 31990936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes.
    Azuma K; Rádiková Z; Mancino J; Toledo FG; Thomas E; Kangani C; Dalla Man C; Cobelli C; Holst JJ; Deacon CF; He Y; Ligueros-Saylan M; Serra D; Foley JE; Kelley DE
    J Clin Endocrinol Metab; 2008 Feb; 93(2):459-64. PubMed ID: 18042650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective Effects of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, against Cisplatin-Induced Nephrotoxicity in Mice.
    Choi SH; Leem J; Lee IK
    Mediators Inflamm; 2017; 2017():4139439. PubMed ID: 29317794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Biomarkers of Kidney Injury and Vascular Calcification in Diabetic Kidney Disease: A Randomized Controlled Trial.
    Trakarnvanich T; Satirapoj B; Suraamornkul S; Chirananthavat T; Sanpatchayapong A; Claimon T
    J Diabetes Res; 2021; 2021():7382620. PubMed ID: 34697593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of gemigliptin as add-on therapy to insulin, with or without metformin, in patients with type 2 diabetes mellitus (ZEUS II study).
    Cho YM; Deerochanawong C; Seekaew S; Suraamornkul S; Benjachareonwong S; Sattanon S; Chamnan P; Sirirak T; Kosachunhanun N; Pratipanawatr T; Suwanwalaikorn S; Lee WJ; Kim S; Choi S; Kang ES; Oh T; Kwon S; Lee MK
    Diabetes Obes Metab; 2020 Jan; 22(1):123-127. PubMed ID: 31478335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postprandial Effect of a High-Fat Meal on Endotoxemia in Arab Women with and without Insulin-Resistance-Related Diseases.
    Al-Disi DA; Al-Daghri NM; Khan N; Alfadda AA; Sallam RM; Alsaif M; Sabico S; Tripathi G; McTernan PG
    Nutrients; 2015 Aug; 7(8):6375-89. PubMed ID: 26247966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
    Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
    Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Dose-Dependent Organ-Specific Effects of a Dipeptidyl Peptidase-4 Inhibitor on Cardiovascular Complications in a Model of Type 2 Diabetes.
    Moon JY; Woo JS; Seo JW; Lee A; Kim DJ; Kim YG; Kim SY; Lee KH; Lim SJ; Cheng XW; Lee SH; Kim W
    PLoS One; 2016; 11(3):e0150745. PubMed ID: 26959365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.